National Cheng Kung University Hospital Nckuh

Tainan 704302

0 studies enrolling now · 9 studies all time

What they study most

Advanced Cancer, Advanced Cholangiocarcinoma, Advanced or Metastatic NSCLC, EGFR Exon 19 Deletion, EGFR L858R, Extensive-stage Small-cell Lung Cancer, FGFR2 Gene Rearrangements, Metastatic Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Nonsquamous Non-small Cell Lung Cancer

Studies at this site

• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Running, not enrolling
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) — Running, not enrolling
• Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — Running, not enrolling
• Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) — Completed
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early
• HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy — Running, not enrolling
• Study of GNX102 in Patients With Advanced Solid Tumors — Stopped early
• Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study — Status unconfirmed